Mixed reality product developer Nreal has garnered $40 million in a Series B1 round of financing led by Beijing Kuaishou Technology, while InxMed Biotechnology (Nanjing) has secured 130 million yuan ($19 million) Series A+ round of financing co-led by China Growth Capital and Qirui Youkang Innovation Fund.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
